Anyone purchased and tried Rilmenidine?

#1

As stated above.

Purchased In the US or ?

Dosing?

#2

I was talking with Ben Blue of Ora Biomedical the other week. They do the most testing of anyone with drugs on c.elegans (worms) and don’t consider anything less than a 40% lifespan increase in these worms as potentially interesting.

The Rilmenidine life extension is only 20% in worms. Not worth wasting your time on (in my view).

See: Rilmenidine Extends Lifespan and Healthspan by 20%

Related: Rilmenidine sources? (I1-imidazoline receptor agonist and elicits similar gnxp to CR)

1 Like
#3

Based on the transcript, Dr. Ben Blue and Dr. Matt Kaeberlein established clear thresholds for what constitutes “meaningful” life extension in C. elegans versus what should be ignored as noise.

  1. The “Ignore” Threshold: 10–15%
    Dr. Blue explicitly stated that he is not interested in interventions that only yield a 10–15% lifespan extension.
  • Reasoning: In C. elegans, a small effect size like this is often statistically significant only because of large sample sizes (e.g., n=200), but it is likely “noise” that will not translate to higher organisms. He argues it is not worth the resources to move these candidates into pre-clinical discovery.
  1. The “Meaningful” Threshold: 40–60%
    Dr. Blue set the bar for “exciting” discovery at 40%, 50%, or 60% life extension.
  • Reasoning: An effect of this magnitude in a worm indicates a robust, undeniable biological impact. If a compound works at “that capacity,” they have high confidence that the biological effect is real and potent enough to potentially translate to mammalian models.
  1. The “Home Run” Scenario: 100% (Worms) → 30% (Mice)
    Dr. Kaeberlein added a translational perspective, noting that if an intervention shows a 100% lifespan extension in worms, it might translate to a 30% extension in mice.
  • Significance: A 30% extension in mice (with health benefits) would make a drug “as good or better than Rapamycin,” which is currently the best-in-class intervention.
    Summary Quote:

“I’m not convinced that a 10% [or] 15% lifespan extension is worth even doing the next steps… I care about seeing stuff that has 40, 50, 60% lifespan extension.” — Dr. Ben Blue

See full episode here Dr. Kaeberlein's Optispan Podcast Series - Rapamycin and More - #119 by RapAdmin

If course different people have different cutoffs levels (in terms of % improvement in lifespan, for different model organisms) for what is interesting. YMMV